Blood-collection technology firm Tasso has been recommended for certification by MDSAP. The international qualification is part of a push to offer the company’s technology in countries such as Australia and Canada, CEO Ben Casavant told Medtech Insight. 

ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.

Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy. 

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.